The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine ...
Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback